Loading candles…
Concord Biotech Limited, incorporated in 1984, is an India-based biopharmaceutical company focused on research and development. The company manufactures fermentation-based active pharmaceutical ingredients (APIs) and finished formulations, specializing in complex and niche molecules such as immunosuppressants and oncology drugs. Concord operates across therapeutic areas including oncology, anti-fungal, and anti-infective treatments. It holds a significant position in the global immunosuppressant market and utilizes its core expertise in fermentation and semi-synthetic processes. The company serves both the Indian and international markets.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 29 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 11 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 8 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 29 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.